🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
549,04 USD
Máx. histórico
558,88
5 días
Split 2:1 del 24/08/2000
Caída desde máximo
-1,76%
Rango 52 semanas
406,67 – 568,67
Variación hoy
+3,44%
Cierre anterior
530,76
Rango de hoy
527,38 – 550,77
Volumen hoy
1.810.311
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 36,82 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 21 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 20/09/2013 | 77,01 | 77,75 | 75,37 | 76,15 | -0,18% | 3,09% | 42.258.300 |
| 19/09/2013 | 77,23 | 77,37 | 76,00 | 76,29 | -1,06% | 1,77% | 2.408.700 |
| 18/09/2013 | 78,18 | 78,53 | 76,69 | 77,11 | -1,18% | 2,35% | 1.685.800 |
| 17/09/2013 | 76,14 | 78,21 | 76,09 | 78,03 | +2,43% | 2,78% | 1.532.900 |
| 16/09/2013 | 79,06 | 79,49 | 75,91 | 76,18 | -2,65% | 4,53% | 1.844.200 |
| 13/09/2013 | 81,29 | 81,30 | 77,07 | 78,25 | -3,87% | 5,20% | 2.737.400 |
| 12/09/2013 | 81,76 | 82,14 | 80,26 | 81,40 | +1,99% | 2,30% | 2.285.600 |
| 11/09/2013 | 81,37 | 81,50 | 79,26 | 79,81 | -1,86% | 2,75% | 974.000 |
| 10/09/2013 | 82,45 | 82,74 | 79,50 | 81,32 | -0,74% | 3,93% | 1.295.700 |
| 09/09/2013 | 79,13 | 82,16 | 78,25 | 81,93 | +3,72% | 4,94% | 1.316.900 |
| 06/09/2013 | 79,06 | 79,20 | 75,73 | 78,99 | +0,78% | 4,39% | 1.500.400 |
| 05/09/2013 | 78,13 | 79,91 | 78,12 | 78,38 | +0,10% | 2,29% | 945.900 |
| 04/09/2013 | 75,43 | 78,55 | 74,91 | 78,30 | +3,87% | 4,83% | 1.279.300 |
| 03/09/2013 | 76,20 | 77,57 | 74,02 | 75,38 | +0,31% | 4,66% | 2.346.400 |
| 30/08/2013 | 77,12 | 77,86 | 74,83 | 75,15 | -2,72% | 3,93% | 2.105.200 |
| 29/08/2013 | 75,79 | 78,15 | 75,54 | 77,25 | +1,73% | 3,44% | 704.600 |
| 28/08/2013 | 75,14 | 77,01 | 74,90 | 75,94 | +1,25% | 2,81% | 1.084.700 |
| 27/08/2013 | 77,03 | 77,38 | 74,67 | 75,00 | -3,78% | 3,52% | 1.055.400 |
| 26/08/2013 | 77,69 | 78,73 | 77,42 | 77,95 | +0,22% | 1,69% | 717.400 |
| 23/08/2013 | 78,40 | 79,00 | 77,29 | 77,78 | -0,79% | 2,18% | 835.900 |
| 22/08/2013 | 76,84 | 78,60 | 76,79 | 78,40 | +2,69% | 2,36% | 779.600 |
| 21/08/2013 | 76,51 | 78,14 | 75,80 | 76,35 | -0,26% | 3,06% | 1.010.400 |
| 20/08/2013 | 75,34 | 77,19 | 75,01 | 76,55 | +1,69% | 2,89% | 953.400 |
| 19/08/2013 | 76,45 | 76,83 | 75,22 | 75,28 | -1,61% | 2,11% | 976.400 |
| 16/08/2013 | 76,86 | 77,36 | 76,25 | 76,51 | -0,58% | 1,44% | 3.036.200 |
| 15/08/2013 | 77,39 | 78,26 | 76,60 | 76,96 | -1,65% | 2,14% | 1.440.000 |
| 14/08/2013 | 77,11 | 78,97 | 76,40 | 78,25 | +0,93% | 3,33% | 1.286.000 |
| 13/08/2013 | 77,69 | 78,07 | 76,04 | 77,53 | +0,06% | 2,61% | 1.679.000 |
| 12/08/2013 | 76,84 | 77,84 | 76,06 | 77,48 | +0,43% | 2,32% | 1.062.400 |
| 09/08/2013 | 77,29 | 78,11 | 76,78 | 77,15 | -0,67% | 1,72% | 798.600 |